Mumps: A year of enhanced surveillance in Catalonia, Spain

Angela Dominguez, Manuel Oviedo, Nuria Torner, Gloria Carmona, Josep Costa, Joan Caylà, M. Rosa Sala, Irene Barrabeig, Neus Camps, Sofia Minguell, Josep Alvarez, Pere Godoy, Josep M. Jansà

Research output: Contribution to journalArticle

Abstract

Mumps is a vaccine-preventable disease candidate for elimination. Positive predictive value (PPV) of clinical case definition was assessed. During 2007, 410 suspected cases were reported in Catalonia: 348 fulfilled clinical case definition and 159 were laboratory confirmed. Incidence rate was 4.8 per 100,000 for cases that fulfilled the clinical definition, and 2.2 for laboratory confirmed cases. Global PPV was 44.5%; 38.5% in <15 years and 50% in ≥15 years (p = 0.04). Most laboratory confirmed cases (72.3%) received at least one MMR dose. With sustained high MMR coverage, laboratory confirmation is necessary to control the disease and assess vaccine failure.

Original languageEnglish (US)
Pages (from-to)3492-3495
Number of pages4
JournalVaccine
Volume27
Issue number25-26
DOIs
StatePublished - May 26 2009

    Fingerprint

Keywords

  • Enhanced surveillance
  • Laboratory confirmation
  • Mumps

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Dominguez, A., Oviedo, M., Torner, N., Carmona, G., Costa, J., Caylà, J., Sala, M. R., Barrabeig, I., Camps, N., Minguell, S., Alvarez, J., Godoy, P., & Jansà, J. M. (2009). Mumps: A year of enhanced surveillance in Catalonia, Spain. Vaccine, 27(25-26), 3492-3495. https://doi.org/10.1016/j.vaccine.2009.03.022